

# Dermatology- New, old, off label and emerging trends for treatment

---

DR MATTHEW HOWARD

MBBS (HONS) MPHIL (HONS) BPHARM (HONS) FACD

CONSULTANT DERMATOLOGIST

NOVUS DERMATOLOGY GEELONG

MONASH HEALTH, EASTERN HEALTH, BARWON HEALTH



# Conflicts of interest

---

I will be discussing off label treatments for some multiple conditions

Consultant and speaker- Johnson and Johnson

# What dermatologists can offer for wounds

---

## Consult on diagnosis of wounds/ulcers


- Often getting diagnosis correct more important than wound dressings
  - e.g. antibiotics for “bilateral lower leg cellulitis” → stasis dermatitis + acute LDS
  - Antibiotics for pyoderma
  - HS managed as recurrent abscess with incision and drainage
  - Calciphylaxis managed as pyoderma

## Assist with performing biopsies

- More tissue the better → incisional biopsy
- Often punch biopsy inadequate specimen/sampling error

## Consult on off label treatment options..



- More to come...



# Old solutions for wounds

## Oral doxycycline

- Doses 50mg daily to 100mg daily (can be BD divided doses)
- Apart from antimicrobial activity (bacteriostatic)...
- Very useful anti-inflammatory effect
  - **Inhibits**
    - Matrix metalloproteinases- 'sculptors' of chronic wound
    - Neutrophil migration
    - Proinflammatory cytokine production
    - Granuloma formation
- Cheap and few drug interactions



# Old solutions for wounds

## Oral doxycycline

- **Many indications!!!**
  - Pyoderma
  - Sweets/neutrophilic conditions
  - Hidradenitis suppurativa
  - Lipodermatosclerosis
  - Immunobullous
  - Granulomatous
  - Necrobiosis lipoidica
- 
- Often used as an adjunctive agent alongside other systemic therapy



# Old solutions for wounds

---

## Pentoxifylline


- Anti TNF alpha inhibition
- Phosphodiesterase inhibitor
- Anti-neutrophilic
- Allows more malleable RBCs for small vessel perfusion
- Mild antiplatelet activity
  
- Dose 400mg daily → TDS



# Old solutions for wounds

## Pentoxifylline


- **Indications**
  - Venous (stasis) ulcer
  - Livedoid vasculopathy/Lymphocytic thrombophilic arteritis
  - Lipodermatosclerosis
  - Necrobiosis lipoidica



Some cost through community pharmacies (50 tabs \$40)- not covered by PBS

- Most hospital pharmacies help subsidise cost for outpatients

GI upset, headache/flushing most common side effects



# New solutions for wounds


## Topical timolol 0.5% eye drops

- apply 1 drop per 1-2 cm squared, Finger as a paint brush

Keratinocytes express abundant  $\beta_2$ -adrenergic receptors-play role in cutaneous homeostasis

## Benefits

- increase extracellular signal-regulated kinase phosphorylation and keratinocyte migration and thus accelerate skin wound re-epithelialization
- Reduce anti-inflammatory cytokine production
- Increase collagen fibre deposition
- Improve angiogenesis
- Inhibit MMP overexpression



# New solutions for wounds

## Topical timolol

- Very safe – used for many years for infantile haemangioma
- Minimal systemic absorption even in infants
- Data exists for
  - Diabetic ulcer
  - Venous ulcers
  - Mixed ulceration (arteriovenous)

Prospective non-randomized observational study:	Multi-center retrospective case series:	Prospective randomized controlled Phase 2 trial:	Phase 3 trial:	Phase 3 trial:
<p><b>Timolol maleate</b> 0.5% (1 drop per 2 cm of wound perimeter) improved healing in chronic diabetic and venous leg ulcers by promoting keratinocyte migration (N=60)<sup>1</sup>.</p>	<p><b>Timolol maleate</b> 0.5% (1 drop per cm<sup>2</sup>) was effective and safe for recalcitrant wounds of various etiologies<sup>2</sup> (N=39).</p>	<p><b>Timolol maleate gel</b> showed benefit and safety for hard-to-heal venous leg ulcers (VLU)<sup>3</sup> (N=43).</p>	<p>FDA-approved ocular <b>timolol maleate gel</b> is currently being tested in a double-blind, randomized controlled trial for diabetic foot ulcers<sup>4</sup> (N=35).</p>	<p>Randomized, double-blind topical application of <b>esmolol 14% gel</b> (<math>\beta</math>1-selective blocker) with SOC demonstrated a significant proportion of ulcer closure within a 12-week treatment period in patients with diabetic foot ulcers<sup>5</sup> N=140</p>
<p>1. Thomas B et al. J Vasc Surg Venous and Lym Dis 2017</p> <p>2. Cahn BA et al, J Drugs Dermatol. 2020</p> <p>3. Baltazard T. et al, Ann Dermatol Venereol 2021</p>			<p>4. Kaur R. et al, ClinicalTrials.gov ID NCT03282981</p> <p>5. Rastogi A et al. JAMA Network Open.2023</p>	



# New solutions for wounds

---

## Topical insulin in the treatment of nonhealing erosions and ulcers of pemphigus vulgaris

- 0.5 to 1 mL insulin (Actrapid human insulin 40 IU/mL sprayed over each ulcer using an insulin syringe. Ulcers were then covered with sterile gauze.
- Repeated BD
- benefit for leg ulcers in case reports
- ↑ vascular endothelial growth factor, transforming growth factor b1, and Ki-67 → angiogenesis and granulation tissue formation



# New solutions for wounds- Biologics

Mainly case series and case report data

No RCT or higher level of evidence data

Off label (\$\$\$) requires compassionate support from hospital and pharmaceutical company

Generally added or substituted when conventional immunosuppression not efficacious/contraindicated


- Main settings
  - Pyoderma Gangrenosum + other neutrophilic
  - Ulcerative NLD/LDS



# New solutions for wounds- Biologics

## Classes of biologics most frequently used


- Anti- TNF alpha
  - Infliximab – IV infusion and now subcut form available
  - Adalimumab- subcut
- Anti IL12/23
  - Ustekinumab- subcut and IV loading
- Anti IL23
  - guselkumab, tildrakizumab etc



# New solutions for wounds- IVIg

## Intravenous immunoglobulin

- Blood product- plasma with immunoglobulin separated
- Pooled from many donors !!
- Expensive \$\$\$\$
- Accessed via hospital – IV infusion
  - Approval from BloodStar (Red Cross)
  - Only certain indications such as Pyoderma/refractory immunobullous/autoimmune etc



# Issues with sorbolene/aqueous creams

---

Inspissated cream!- leaving on cream and not removing excess/residue

Fragrances + preservatives- Allergic contact dermatitis risk!!

pH not optimised for skin- pH for both higher!

Poor quality moisturisers

- Many better on market
- Ceramide containing- CeraVe, QV with ceramides, Cetaphil
- Silicone containing- Strata CTX



# Dermatitis artefacta

---

A modern epidemic!

Especially in post COVID mental health pandemic

Patients self induce skin lesions as maladaptive response to psychological stress

- Clues
  - Unusual / geometric shapes
  - Linear
  - Co-existent mental health
  - Location on body that can be reached
  - Heal when under supervision/occlusive dressing



# Dermatitis artefacta

---

Often patients deny having created lesions

In adults often poor prognosis

In my personal experience limited psych support

- Have even had psychiatrists support patients insistence for “missed” organic diagnosis

In many cases require biopsies, bloods, cultures to exclude differentials



# Skin decontamination

---

Dilute vinegar soaks- antipseudomonal 1:10 water

Bleach and hypochlorous acid-

- 1/2 cup(125 mL) of demineralised water with 1/4 cup (60 mL) of white vinegar
- Slowly add 1/2 teaspoon (2.5 mL) of baking soda while stirring the solution until no further bubbles are produced.
- Finally add two teaspoons (10 mL) of Milton sanitising solution.
- 0.04% hypochlorous acid solution has a pH of approximately 5, similar to the pH of the skin.
  - stored away from direct sunlight.
- liquid or gel can be made by adding a small amount of xanthan gum or gelatine powder Potassium permanganate- dilute to light rose- astringent and antimicrobial

Burrows solution- aluminium acetate 3-15%- astringent and antimicrobial

Prontosan costly

BlastX- risk of allergic and irritant contact dermatitis

- PEG & Benzalk Chloride

# A case for call to action

---

- Acute wards, outpatients and EDs under more and more pressure
  - Tight budgets and increasing healthcare costs with an ageing population,
  - >1000 patients under management in Barwon Health alone with chronic wounds,
- Wound care clinician involvement becomes even more important!

# A case for call to action

---

- 49 year old male
- Referred for inpatient dermatology consultation by wound care nurse
- Admitted under colorectal team **multiple months** in acute hospital!!!
- Perforated sigmoid diverticulitis → multi quadrant peritonitis → sepsis
- Multiple attempts to re-approximate wound due to suspected dehiscence
- Concern from wound nurse of pathergy/PG response prompted referral
- Suicidal and medically deteriorating
  
- Distant history of GPA in remission, however repeat bloods post derm consultation
  - cANCA >200 with signs of PG on biopsy with necrotizing granuloma in lungs
- Treatment
  - topical corticosteroids to wound edge, IVIg, IV methylprednisolone 500mg x3 followed by rituximab 1g two weeks apart and weaning prednisolone
  - Promptly discharged within 1.5 weeks to rehabilitation

# References

---

- Sun et al 2024- Efficacy and Safety of Pentoxifylline for Venous Leg Ulcers: An Updated Meta- Analysis. *The International Journal of Lower Extremity Wounds* 23(2) 264–274
- Salih et al 2024 A systematic review and meta-analysis assessing the impact of pentoxifylline on the healing and recurrence of venous leg ulcers. *Phlebology* 0(0) 1-7
- Sadler et al 2012 Oral doxycycline for the treatment of chronic leg ulceration *Arch Dermatol Res* 304:487–493
- Kargin et al 2015 The Effects of Topical Insulin Application on Wound Healing *Eur J Gen Med* 2015; 12(4):302-306
- Liu et al 2021 Effects of topical insulin on wound healing: a metaanalysis of animal and clinical studies. *Endocrine Journal* 68(8) 969-79
- Cahn et al 2020 Use of topical timolol maleate as re-epithelialisation agent for treatment of recalcitrant wounds of varying etiologies. *J Drugs in Dermatol* 19(12)
- Nagesh et al 2023 Dermatitis Artefacta. *Clinics in Dermatology*. Volume 41, Issue 1, January–February 2023, Pages 10-15

Thank you

---